Truist Financial
MDGL icon

Truist Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Truist Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$287K Sell
549
-20
-4% -$9.55K ﹤0.01% 2416
2025
Q4 		$331K Sell
569
-34
-6% -$17.4K ﹤0.01% 2269
2025
Q3 		$277K Buy
+603
New +$225K ﹤0.01% 2371
2024
Q3 		– Sell
-772
Closed -$216K – 2633
2024
Q2 		$216K Buy
+772
New +$184K ﹤0.01% 2462

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Truist Financial's MDGL Position: Q1 2026 in Review

Truist Financial reduced its Madrigal Pharmaceuticals (MDGL) stake by 3.5% in Q1 2026, selling an estimated $9.55K and leaving 549 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #2416.

Truist Financial first reported a position in MDGL in Q2 2024 and has held it in 4 quarters since. The position peaked at $331K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Truist Financial held 549 shares of Madrigal Pharmaceuticals worth $287K as of Q1 2026.
  • Truist Financial sold 20 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $9.55K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Truist Financial's portfolio in Q1 2026, its #2416 holding.
  • Truist Financial first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
  • Truist Financial's Madrigal Pharmaceuticals position peaked at $331K in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Truist Financial's 13F filing for Q1 2026, filed 27 Apr 2026.